Gilead insider Wilfong granted 921 RSUs, sells 338 shares at $115.25

Rhea-AI Filing Summary

Gilead Sciences insider Diane E. Wilfong, identified as Interim Corporate Controller & CAO, reported transactions on 09/10/2025. She was credited with 921 restricted stock units (RSUs) that represent rights to 921 shares subject to a four-year vesting schedule (25% at year one, then 6.25% quarterly). The filing also shows a disposition of 338 shares at a price of $115.25 each. After the transactions, Ms. Wilfong directly beneficially owns 46,259 common shares and holds 7,864 RSUs outstanding. The Form 4 is signed by power of attorney on 09/11/2025.

Positive

• 921 RSUs granted/credited representing potential alignment of executive and shareholder interests as they vest
• Clear disclosure of vesting schedule: 25% at first anniversary, then 6.25% quarterly

Negative

• None.

Insights

Financial Analyst

TL;DR: Routine equity compensation vesting with a small open-market sale; immaterial to company valuation.

The reported activity reflects standard executive compensation mechanics: grant and vesting of RSUs plus an isolated sale of a small block of shares at $115.25. The addition of 921 RSUs increases potential future dilution only as they vest, and the filing shows 7,864 outstanding RSUs for this reporting person. The 338-share disposition is small relative to a public company and does not change disclosed direct ownership materially (46,259 shares held post-transaction). There are no indications of accelerated vesting, loans, or derivative strategies that would raise governance or liquidity concerns.

Corporate Governance Expert

TL;DR: Disclosure aligns with Section 16 reporting; vesting schedule and sale are documented and routine.

The Form 4 provides clear description of the RSU terms (one share per unit, four-year schedule with 25% after one year and 6.25% quarterly thereafter) and reports the acquisition and disposition codes appropriately. Signature by power of attorney is noted and acceptable. From a governance perspective, the filing meets transparency expectations for insider holdings and transactions; no unusual timing, related-party transfers, or plan-based exceptions are disclosed.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Wilfong Diane E.

(Last) (First) (Middle)

GILEAD SCIENCES, INC.

333 LAKESIDE DRIVE

(Street)

FOSTER CITY CA 94404

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
GILEAD SCIENCES, INC. [ GILD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Interim Corp Controller & CAO

3. Date of Earliest Transaction (Month/Day/Year)
09/10/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/10/2025		M		921	A	(1)	46,597	D
Common Stock	09/10/2025		F		338	D	$115.25	46,259	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Unit	(1)	09/10/2025		M			921	(2)	(2)	Common Stock	921	(1)	7,864	D

Explanation of Responses:

1. Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.

2. The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested.

Remarks:

	/s/ Edward S. Son by Power of Attorney for Diane E. Wilfong	09/11/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What transactions did GILD insider Diane Wilfong report on 09/10/2025?

She received 921 RSUs and sold 338 common shares at $115.25 each; filings show post-transaction holdings of 46,259 shares and 7,864 RSUs.

How do the restricted stock units for GILD reported by Diane Wilfong vest?

They vest over four years: 25% on the first anniversary of the grant date and the remaining balance at 6.25% quarterly until fully vested.

How many shares does Diane Wilfong own after the reported Form 4 transactions for GILD?

46,259 shares directly beneficially owned and 7,864 RSUs outstanding per the Form 4.

At what price were shares sold in the GILD Form 4 filed by Diane Wilfong?

338 shares were disposed of at $115.25 per share as reported on the Form 4.

Who signed the Form 4 for Diane Wilfong and when?

Edward S. Son signed by Power of Attorney on behalf of Diane E. Wilfong, dated 09/11/2025.